¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"progressive resistance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acoustic resistance
    À½ÇâÀúÇ×
  • acquired resistance
    ȹµæÀúÇ×
  • airway resistance
    ±âµµÀúÇ×
  • bladder outlet resistance
    ¹æ±¤ÃⱸÀúÇ×
  • coronary vascular resistance
    °ü»óÇ÷°üÀúÇ×, ½ÉÀåÇ÷°üÀúÇ×
  • cross-resistance
    ±³Â÷ÀúÇ×
  • cerebral vascular resistance
    ³úÇ÷°üÀúÇ×
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
  • electric skin resistance
    ÇǺÎÀü±âÀúÇ×
  • flow resistance
    È帧ÀúÇ×, À¯·®ÀúÇ×
  • frictional resistance
    ¸¶ÂûÀúÇ×
  • genetic resistance
    À¯ÀüÀúÇ×
  • heterogeneous resistance
    ºñ±ÕÀÏÀúÇ×
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acquired resistance
    ȹµæÀúÇ×
  • airway resistance
    ±âµµÀúÇ×
  • antibiotic resistance
    Ç×»ýÁ¦³»¼º
  • resistance amplification
    ÀúÇ×ÁõÆø
  • bladder outlet resistance
    ¹æ±¤ÃⱸÀúÇ×
  • cross-resistance
    ±³Â÷ÀúÇ×
  • cerebral vascular resistance
    ³úÇ÷°üÀúÇ×
  • coronary vascular resistance
    ½ÉÀåÇ÷°üÀúÇ×, °ü»óÇ÷°üÀúÇ×
  • cross resistance
    ±³Â÷³»¼º
  • resistance coil
    ÀúÇ×ÄÚÀÏ
  • donor resistance
    ÁÖ´ÂÀÌÀúÇ×¼º
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • resistance donor
    ÀúÇ×¼ºÁ¦°øÃ¼, ÀúÇ×¼ºÁÖ°Ô
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • progressive case
    ÁøÇ༺ ¿¹.
  • progressive deafness
    ÁøÇà(¼º) ³­Ã»
  • progressive deafness
    ÁøÇ༺ ³­Ã»(òäú¼àõ Ññôé)
  • progressive diaphyseal dysplasia
    ÁøÇ༺ °ñ°£¼º ÀÌÇü¼º(Áõ)(òäú¼àõÍéÊÏàõì¶ û¡à÷ñø).
  • progressive diaphyseal dysplasia
    ÁøÇ༺ °ñ°£¼º ÀÌÇü¼º(Áõ)(òäú¼àõ ÍéÊÏàõ ì¶û¡à÷(ñø))
  • progressive diffuse keratoderma
    ÁøÇ༺ ±¤¹üÀ§ °¢ÇÇÁõ
  • progressive external ophthalmoplegia
    ÁøÇ༺¿Ü¾È±Ù¸¶ºñ
  • progressive facial paralysis
    ÁøÇà(¼º) ¾È¸é¸¶ºñ
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(¡­ãêÌèæú).
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(òäú¼àõ Ýþý§àõ ÊÖòðàõ ãêÌèæú)
  • progressive idiopathic atrophoderma
    ÁøÇ༺ ¿øÀÎºÒ¸í¼º ÇǺΠÀ§ÃàÁõ
  • progressive lenticular degeneration
    ÁøÇ༺ ·»ÁîÇÙº¯¼º(Áõ)(òäú¼àõ¡­ú·Ü¨àõ(ñø))
  • progressive lingual hemiatrophy
    ÁøÇà(¼º) ¹ÝÃø¼³À§ÃàÁõ
  • progressive lingual hemiatrophy
    ÁøÇ༺ ¹ÝÃø¼³À§ÃàÁõ(òäú¼àõ Úâö°àßê×õêñø)
  • progressive lipodystrophy
    ÁøÇ༺ Áö¹æÀÌ¿µ¾çÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • progressive disseminated histoplasmisis
  • progressive external ophthalmoplegia
    ÁøÇ༺¿Ü¾È±Ù¸¶ºñ
  • progressive external opthalmoplegia
  • progressive facial paralysis
    ÁøÇà(¼º) ¾È¸é¸¶ºñ
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(¡­ãêÌèæú).
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(òäú¼àõ Ýþý§àõ ÊÖòðàõ ãêÌèæú)
  • progressive idiopathic atrophoderma
    ÁøÇ༺ ¿øÀÎºÒ¸í¼º ÇǺΠÀ§ÃàÁõ
  • progressive lenticular degeneration
    ÁøÇ༺ ·»ÁîÇÙº¯¼º(Áõ)(òäú¼àõ¡­ú·Ü¨àõ(ñø))
  • progressive lingual hemiatrophy
    ÁøÇà(¼º) ¹ÝÃø¼³À§ÃàÁõ
  • progressive lingual hemiatrophy
    ÁøÇ༺ ¹ÝÃø¼³À§ÃàÁõ(òäú¼àõ Úâö°àßê×õêñø)
  • progressive lipodystrophy
    ÁøÇ༺ Áö¹æÀÌ¿µ¾çÁõ.
  • progressive lipodystrophy
    ÁøÇ༺ Áö¹æÀÌ¿µ¾çÁõ(òäú¼àõ ò·Û¸ì¶ç½å×ñø)
  • progressive mean
    ´©°¡Æò±Õ(ËÈ˧̰˻).
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´Ù¹ß¼º ¹éÁú³ú(º´)Áõ
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´ÙÃÊÁ¡¼º ¹éÁú³úº´Áõ(òäú¼àõ Òýõ¥ïÇàõ ÛÜòõÒàÜ»ñø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
PVR peripheral vascular resistance; perspective volume rendering; poliovirus receptor; postvoiding resid...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
TPR temperature, pulse, and respiration; testosterone production rate; third party reimbursement; total ...
TPVR total peripheral vascular resistance; total pulmonary vascular resistance
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PME Progressive Myoclonus Epilepsy
PR Progressive Ratio
PSP Progressive supranuclear paly
PSS Progressive Systemic Scleroderma
PSS Progressive Systemic Sclerosis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug resistance transfer factor
    ¾àÁ¦ ³»¼º Àü´Þ ÀÎÀÚ
  • flow resistance
    È帧 ÀúÇ×, À¯·® ÀúÇ×
  • hepatic vascular resistance
    °£ Ç÷°ü ÀúÇ×
  • immunological resistance
    ¸é¿ª ÀúÇ×
  • magnetic resistance
    ÀÚ±â ÀúÇ×
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • peripheral resistance unit
    ¸»ÃÊ ÀúÇ× ´ÜÀ§
  • platinum resistance furnace
    Àü±â ¼Ò¼º·Î, ¹é±Ý ·Î
  • radiation resistance
    ¹æ»ç¼± ÀúÇ×
  • resistance
    °ÅºÎ, ÀúÇ×, ÀúÇ×¼º, ³»¼º
    Àü·ù Åë°ú¿¡ ´ëÇÏ¿© µµÃ¼¿¡ ÀÇÇÑ ÀúÇ×. Á¤½Å ºÐ¼®¿¡ À־´Â ¾ï¾ÐµÈ °ÍÀÌ ÀǽÄÀ¸·Î µÇ´Â °Í¿¡ ´ëÇÑ ÀúÇ×. Á¤»óÀÇ »ý¹°ÀÌ È¯°æ³»ÀÇ µ¶¹°, ¿¹ÄÁµ¥ µ¶, µ¶¼Ò, Àڱع°, º´¿ø¼º ¹Ì»ý¹° µî¿¡ ´ëÇÏ¿© ÀÚ¿¬ÀûÀ¸·Î °®´Â ³»¼º.
  • resistance factor
    ³»¼º ÀÎÀÚ
  • resistance form of cavity
    ¿Íµ¿ÀÇ ÀúÇ× ÇüÅÂ
  • resistance reflex
    ÀúÇ× ¹Ý»ç
  • resistance to corrosion
    ³»½Ä¼º
  • sleep resistance
    Àá ÅõÁ¤
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
cross-resistance <immunology, microbiology> Immunologic resistance to the pathogenic effects of a microorganism because of previous exposure to another species or type having cross reactive antigens.
This phenomenon is seen in microbes that acquire resistance to one drug through direct exposure and turn out to have resistance to one or more other drugs to which it has not been exposed. Cross-resistance arises because the mechanism of resistance to several drugs is the same and arises through the identical genetic mutations.
(09 Oct 1997)
sisomicin-gentamicin resistance ribosomal RNA methylase <enzyme> Catalyses the methylation of 30s ribosomal units to confer sisomicin-gentamicin resistance in micromonospora zionensis
Registry number: EC 2.1.1.-
Synonym: sgm gene product, sgm methylase
(26 Jun 1999)
synaptic resistance The ease or difficulty with which a nerve impulse can cross a synapse.
(05 Mar 2000)
systemic vascular resistance An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output.
(05 Mar 2000)
dicumarol resistance A well-defined autosomal dominant resistance to it, over and above general variability in tolerance to the drug.
(05 Mar 2000)
drug resistance The ability of bacteria and other microorganisms to withstand a drug to which they were once sensitive (and were once stalled or killed outright).
(12 Dec 1998)
drug resistance, microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through plasmids containing resistance factors (r factors).
(12 Dec 1998)
drug resistance, multiple Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein.
(12 Dec 1998)
drug resistance, neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
(12 Dec 1998)
impact resistance The ability of a lens for eyewear to withstand impact without shattering or breaking, i.e., of a 3/8 -inch steel ball dropped 50 feet; criteria for determination of impact resistance are specified by U.S. Regulations.
(05 Mar 2000)
inductive resistance The weakening of an alternating electric current by passage through a coil of wire or a condenser.
Synonym: inductive resistance.
(05 Mar 2000)
insecticide resistance The development by insects of resistance to insecticide.
(12 Dec 1998)
insulin resistance Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range.
(09 Oct 1997)
tetracycline resistance Nonsusceptibility of a microbe (usually a bacterium) to the action of tetracycline, which binds to the 30s ribosomal subunit and prevents the normal binding of aminoacyl-trna.
(12 Dec 1998)
thyroid hormone resistance syndrome <syndrome> An inherited syndrome of peripheral resistance to thyroid hormones, transmitted as an autosomal recessive trait, characterised by increased serum concentrations of thyroxine and triiodothyronine, increased thyroid hormone binding ratio, and normal to slightly increased thyroid-stimulating hormone and its response to thyrotropin-releasing hormone. The affected persons are euthyroid to slightly hypothyroid. The absence of hypermetabolism and the presence of possible hypothyroidism indicate the existence of partial resistance to the peripheral action of thyroid hormone.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á